Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ocular Pathologies Clear all
Not listed No phase listed Observational

Intraoperative Hyperoxia and MINS

NCT04540276
View directory record Official record
Conditions
Hyperoxia, Myocardial Infarction, Myocardial Injury
Interventions
Inspiratory oxygen fraction
Drug
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Other
Eligibility
18 Years and older
Enrollment
7,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

NCT00001596
View directory record Official record
Conditions
Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
William Gahl, M.D.
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Jul 22, 2026, 9:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT03686124
View directory record Official record
Conditions
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Interventions
IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect®
Biological · Drug · Device
Lead sponsor
Immatics US, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 9:51 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Innovations in Glaucoma Study

NCT00221897
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Myopia
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 22, 2026, 9:51 AM EDT
Not yet recruiting Not applicable Interventional

Effectiveness of VestAid App

NCT06683417
View directory record Official record
Conditions
MTBI - Mild Traumatic Brain Injury, Vestibular Disease, Balance Deficits, Vestibular Disorders, Dizziness
Interventions
Vestibular Rehabilitation Aid, Standard of care vestibular rehabilitation
Device · Other
Lead sponsor
BlueHalo
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 22, 2026, 9:51 AM EDT
Terminated Phase 4 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT04707625
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

First-Sight Refractive Error Correction in the Developing World

NCT01598818
View directory record Official record
Conditions
Vision Loss
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
7 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Multimodal Physician Intervention to Detect Amblyopia

NCT01109459
View directory record Official record
Conditions
Amblyopia, Strabismus
Interventions
Pediatric blood pressure screening, Pediatric vision screening
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2010 · Synced Jul 22, 2026, 9:51 AM EDT
Recruiting No phase listed Interventional

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old

NCT00944710
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Fullerton, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 22, 2026, 9:51 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility of Stimulating the Visual Cortex in Blind

NCT02747589
View directory record Official record
Conditions
Blindness,Acquired
Interventions
Surgical device implant in brain
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 74 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

NCT01578720
View directory record Official record
Conditions
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
Interventions
EYLEA (Aflibercept) intravitreal injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 22, 2026, 9:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Light-deprivation Utilized to Mitigate Amblyopia

NCT02685423
View directory record Official record
Conditions
Amblyopia
Interventions
Binocular deprivation 10 days, Vision training
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jul 22, 2026, 9:51 AM EDT
Not listed Phase 2 Interventional

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

NCT05077280
View directory record Official record
Conditions
Uveal Melanoma
Interventions
stereotactic body radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Jul 22, 2026, 9:51 AM EDT
Terminated No phase listed Observational

Tissue Studies of Human Eye Diseases

NCT00001310
View directory record Official record
Conditions
Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis, Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
3,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jul 22, 2026, 9:51 AM EDT
Completed No phase listed Observational

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

NCT01287247
View directory record Official record
Conditions
Cervical Dystonia, Blepharospasm
Interventions
Xeomin®
Biological
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
70
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 22, 2026, 9:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Connection Between Areas in the Brain of Blind Patients

NCT00001926
View directory record Official record
Conditions
Blindness, Brain Mapping, Healthy
Interventions
O15, Cadwell rTMS
Drug · Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:51 AM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Jul 22, 2026, 9:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Information Processing Biases in Adults Who Stutter

NCT06422442
View directory record Official record
Conditions
Stuttering, Adult
Interventions
Threat-related stimulus exposure
Behavioral
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

NCT01847638
View directory record Official record
Conditions
Cataract, Retinal Edema, Inflammation
Interventions
Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
Drug
Lead sponsor
Melissa Toyos
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Comparing Patient Satisfaction With Pataday or Bepreve

NCT01450176
View directory record Official record
Conditions
Eye Allergies
Interventions
Olopatadine hydrochloride 0.2%, Bepotastine besilate ophthalmic solution 1.5%
Drug
Lead sponsor
McCabe Vision Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 9:51 AM EDT
Withdrawn Not applicable Interventional

Simulated Walking With Multiplexing Prism for Field Expansion in Monocular Vision

NCT06024668
View directory record Official record
Conditions
One Eye Blindness, Blind Left Eye, Blind Right Eye
Interventions
Multiplexing Prism
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

NCT00429923
View directory record Official record
Conditions
Inflammation
Interventions
Difluprednate, Placebo
Drug
Lead sponsor
Sirion Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
219 participants
U.S. locations
1
States / cities
Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2009 · Synced Jul 22, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

NCT00030108
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 22, 2026, 9:51 AM EDT